# Progress Note 07 — Preventive Visit

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Gilda Radner (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML026-SYN
- Date: 2026-10-13
- Fictional facility: St. Posthumous Health Center
- Fictional author: Delia Marchand, MD
- Calendar frame: modern shifted

- Visit type: Preventive Visit
- Services: CPT 99396 (periodic preventive medicine, established patient, age 40 to 64) with CPT 99497 (advance care planning) on the same day

## Chief complaint

Periodic adult preventive visit, four weeks into olaparib. **S**

## History of present illness

Ms. Radner, now 40, comes for her yearly preventive visit four weeks after starting olaparib maintenance. She finished six cycles of carboplatin and paclitaxel seven weeks ago; the end-of-treatment CT showed no evidence of disease and her CA-125 was 9. On olaparib she has mild nausea in the first hour after the morning dose, which settles if she takes it with food, and she tires in the late afternoon. She has no breathlessness, cough, fever, or bruising. The tingling in her toes is fading. Hot flashes wake her two or three nights a week; she has chosen to wait on hormone therapy for now. She goes to a support group at a cancer support community every other week and is writing again. Her PHQ-9 today is 2. **S**

| Element | Detail |
|---|---|
| Visit | Periodic adult preventive visit, age 40 |
| Active conditions | Stage IIIC high-grade serous ovarian cancer, no evidence of disease after surgery and chemotherapy; on olaparib for four weeks |
| Medicines | Olaparib 300 mg twice daily; ondansetron when needed, used twice this month |
| Olaparib effects | Mild morning nausea, afternoon tiredness; no breathlessness or bruising |
| Menopause | Hot flashes two or three nights a week; hormone therapy deferred by her choice |
| Mood | PHQ-9 2; attends a support group |

## Health risk assessment

Completed by the patient on a tablet in the waiting room and reviewed with her by Dr. Marchand. **S**

| Domain | Finding |
|---|---|
| Self-rated health | Good and improving |
| Psychosocial | Supported by her spouse and friends; a support group every other week; back to writing and some work |
| Tobacco | Never smoked |
| Alcohol and drugs | A glass of wine on some weekends (AUDIT-C 1); no drugs |
| Physical activity | Walks 30 minutes most days; building up after treatment |
| Nutrition | Three small meals and snacks; appetite back; weight up 1.4 kg since the end of chemotherapy |
| Sleep | Six to seven hours, broken by hot flashes two or three nights a week |
| Sexual health | Vaginal dryness since surgery; using a moisturizer |
| Safety at home | Feels safe; no one hurts, threatens, or controls her; no firearm in the home |
| Road safety | Wears a seat belt |
| Activities of daily living | Independent |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Afternoon tiredness; no fever, night sweats, or weight loss |
| Eyes | Negative | No vision change |
| Ears, nose, mouth, and throat | Negative | No mouth sores or hearing change |
| Cardiovascular | Negative | No chest pain, palpitations, or leg swelling |
| Respiratory | Negative | No cough or breathlessness |
| Gastrointestinal | Positive | Mild nausea after the morning dose; no bloating, early fullness, or change in bowel habit |
| Genitourinary | Positive | Vaginal dryness; no urinary symptoms or vaginal bleeding |
| Musculoskeletal | Negative | No joint or bone pain |
| Integumentary | Negative | Hair growing back; no rash or bruising |
| Neurological | Positive | Slight tingling in the toes, fading; no weakness or falls |
| Endocrine | Positive | Hot flashes two or three nights a week |
| Psychiatric | Negative | Mood good; PHQ-9 2; no thoughts of self-harm |
| Hematologic and lymphatic | Negative | No bruising, bleeding, or swollen glands |

13 systems reviewed. **S**

## Current medications

- Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nausea **S**
- Olaparib 150 mg oral tablet, two tablets (300 mg) by mouth twice daily with food, as maintenance for up to two years **S**

## Allergies

- No known allergy **S**

## Objective

BP 112/70 mmHg; pulse 74 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 57.2 kg; BMI 22.3 kg/m². All vital signs are synthetic.

Hemoglobin: 10.6 g/dL (low); White cell count: 4.2 10*3/uL; Absolute neutrophil count: 2.4 10*3/uL; Platelets: 182 10*3/uL; Total cholesterol: 186 mg/dL; HDL cholesterol: 58 mg/dL; LDL cholesterol: 108 mg/dL; Triglycerides: 98 mg/dL; PHQ-9: 2; AUDIT-C: 1. All results are synthetic.

## Change since baseline

- Hemoglobin: 12.4 g/dL at baseline, 10.6 g/dL (low) at this visit **S**
- White cell count: 7.8 10*3/uL at baseline, 4.2 10*3/uL at this visit **S**
- Platelets: 412 10*3/uL (high) at baseline, 182 10*3/uL at this visit **S**

## Immunizations given today

- Influenza vaccine, this season (inactivated) **S**
- COVID-19 mRNA vaccine, this season's formula **S**
- Pneumococcal conjugate vaccine (PCV20) **S**
- Recombinant zoster vaccine, dose 1 of 2 **S**

## Physical examination

| System | Finding |
|---|---|
| Constitutional | Well; weight 57.2 kg, BMI 22.3; blood pressure 112/70 |
| Head, eyes, ears, nose, and throat | No mouth ulcers; short regrowing hair |
| Neck | Thyroid normal; no lymph nodes |
| Breasts | No mass, skin change, or nipple discharge on either side; no axillary nodes |
| Cardiovascular | Regular rhythm; no murmur; no leg swelling |
| Respiratory | Clear to auscultation bilaterally |
| Abdomen | Midline scar healed; soft, non-tender, no mass, no fluid |
| Lymph nodes | No cervical, supraclavicular, axillary, or inguinal nodes |
| Neurological | Light touch slightly reduced over the tips of the toes; vibration sense and ankle reflexes normal; steady gait |
| Skin | No rash, bruising, or suspicious lesions |
| Psychiatric | Bright and funny; organized; engaged |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Periodic adult preventive visit completed**. Health risk assessment reviewed and the prevention plan updated for a woman of 40 after ovarian cancer treatment. Total cholesterol 186, HDL 58, LDL 108 mg/dL; ten-year cardiovascular risk under 2 percent, so no statin. Mammography is due now that she is 40. Cervical screening is no longer needed because the cervix was removed for a cancer that was not cervical. Vaccines for an adult after chemotherapy are given today, with no live vaccine. **S**
   - Influenza, COVID-19, PCV20 and the first recombinant zoster dose given today; the second zoster dose in two to six months.
   - Screening mammogram ordered.
   - Baseline bone density scan ordered after surgical menopause.
   - Next preventive visit in one year.
2. **High-grade serous ovarian cancer, stage IIIC, no evidence of disease, on olaparib maintenance** (C56.3). Four weeks of olaparib, well tolerated. Monthly blood count today: hemoglobin 10.6 g/dL, a mild fall from 11.2 at the start, with white cells 4.2, neutrophils 2.4 and platelets 182; no dose change is needed. No breathlessness or new cough to suggest pneumonitis. **S**
   - Continue olaparib 300 mg twice daily with food.
   - Blood count again in four weeks.
   - Gynecologic oncology review with CA-125 three months after the end of chemotherapy.
3. **Symptomatic surgical menopause** (E89.41). Hot flashes two or three nights a week and vaginal dryness. Hormone therapy was discussed at the end of chemotherapy and is not ruled out by her cancer type; she prefers to wait. **S**
   - Vaginal moisturizer; layered bedding and a fan.
   - Revisit hormone therapy or a non-hormonal medicine at the next visit if sleep worsens.
   - Bone density scan as above.
4. **Chemotherapy-induced peripheral neuropathy** (G62.0). Mild and fading seven weeks after the last paclitaxel; no effect on balance. **S**
   - Foot checks and well-fitting shoes; report any fall.

## Personalized prevention plan

A written copy was given to the patient. **S**

| Service | Status | Detail |
|---|---|---|
| Blood pressure screening | Completed today | 112/70 mmHg |
| Depression screening | Completed today | PHQ-9 score 2; item 9 scored 0 |
| Unhealthy alcohol use screening | Completed today | AUDIT-C score 1 |
| Tobacco use | Completed today | Never smoked |
| Intimate partner violence screening | Completed today | Negative; she feels safe |
| Breast cancer screening | Ordered | Screening mammogram every two years from 40; first one ordered today. Her germline panel was negative, so no extra breast imaging is needed for a variant |
| Cervical cancer screening | Not indicated | Cervix removed at a hysterectomy for ovarian cancer, with no history of cervical precancer |
| Colorectal cancer screening | Not indicated | Starts at 45; no family history of bowel cancer; Lynch syndrome genes negative on her panel |
| Cholesterol screening and statin decision | Completed today | Total cholesterol 186, HDL 58, LDL 108 mg/dL; ten-year risk under 2 percent; no statin |
| Diabetes screening | Not indicated | BMI 22.3 with no other risk factor |
| Osteoporosis screening | Ordered | Postmenopausal after surgery at 39, so a baseline bone density scan is reasonable |
| Hepatitis B, hepatitis C and HIV screening | Up to date | All negative before chemotherapy |
| Ovarian cancer screening | Not indicated | Screening is for women without symptoms; she is under cancer surveillance with gynecologic oncology |
| Influenza vaccine | Completed today | Inactivated vaccine given |
| COVID-19 vaccine | Completed today | This season's mRNA vaccine given |
| Pneumococcal vaccine | Completed today | PCV20 given, for an adult under 50 after cancer chemotherapy |
| Recombinant zoster vaccine | Completed today | Dose 1 given, for an adult under 50 after cancer chemotherapy; dose 2 in two to six months |
| Tetanus, diphtheria, and pertussis | Up to date | Tdap five years ago |
| Live vaccines (MMR, varicella) | Not indicated | Immune from childhood doses; live vaccines are avoided within three months of chemotherapy |
| Dental examination | Due | Last visit before chemotherapy; to book a cleaning now that counts have recovered |

## Advance care planning

Voluntary advance care planning discussion of about 20 minutes, with her consent. She named a health care agent, recorded in the confidential part of the chart and not named here. She said that she wants to be told the truth about her illness plainly and in person, that she would want treatment aimed at living longer as long as she can still enjoy her days and be herself, and that if that were no longer possible she would want comfort and to be awake enough to know the people around her. She completed a health care proxy form and will think about a written living will. To be revisited at each change in her health and at least yearly. **S**

## Guideline basis

- Tew WP, et al. PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline. J Clin Oncol 2020;38(30):3468-3493 (2020), American Society of Clinical Oncology
- Salani R, et al. An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations. Gynecol Oncol 2017;146(1):3-10 (2017), Society of Gynecologic Oncology
- Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026), Aether Forge
- USPSTF A and B Recommendations (2026), U.S. Preventive Services Task Force
- Breast Cancer: Screening (2024), U.S. Preventive Services Task Force
- Adult Immunization Schedule by Medical Condition and Other Indication (2026), Centers for Disease Control and Prevention

## Follow-up

- Mammogram and bone density scan within the month. Blood count in four weeks. Gynecologic oncology review in about five weeks. Second zoster dose in two to six months. Next preventive visit in one year. **S**

